Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.48 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.48 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.48 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.45 |
| ▸ | BACE1 | P56817 | 7/20 | 0.44 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.42 |
| ▸ | CPB2 | Q96IY4 | 3/20 | 0.42 |
| ▸ | NPY1R | P25929 | 1/20 | 0.41 |
| ▸ | NPY2R | P49146 | 1/20 | 0.41 |
| ▸ | NPY4R | P50391 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | CTSD | P07339 | 1/20 | 0.41 |
| ▸ | NMT2 | O60551 | 1/20 | 0.40 |
| ▸ | NMT1 | P30419 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31211799 | 0.95 | ERAP2 (0.51) | ERAP2ERAP1LNPEPFOLH1NOD1 | |
| SCHEMBL31750957 | 0.95 | BACE1 (0.48) | ERAP2ERAP1LNPEPFOLH1BACE1 | |
| SCHEMBL29760983 | 0.95 | BACE1 (0.48) | ERAP2ERAP1LNPEPFOLH1BACE1 | |
| SCHEMBL31042502 | 0.95 | BACE1 (0.48) | ERAP2ERAP1LNPEPFOLH1BACE1 | |
| SCHEMBL29777802 | 0.92 | FOLH1 (0.55) | ERAP2ERAP1LNPEPFOLH1BACE1 | |
| SCHEMBL29777885 | 0.92 | FOLH1 (0.48) | FOLH1BACE1NOD1CPB2CTSD | |
| SCHEMBL30734094 | 0.92 | FOLH1 (0.48) | FOLH1BACE1NOD1CPB2CTSD | |
| SCHEMBL30193776 | 0.91 | ERAP2 (0.54) | ERAP2ERAP1LNPEPFOLH1NOD1 | |
| SCHEMBL31412174 | 0.91 | ERAP2 (0.54) | ERAP2ERAP1LNPEPFOLH1NOD1 | |
| SCHEMBL30193296 | 0.91 | ERAP2 (0.54) | ERAP2ERAP1LNPEPFOLH1NOD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11633459-B2 | GIP derivatives and uses thereof | NOVO NORDISK A/S (DK) | 2023-04-25 | — | — | US | claimed |
| US-20240190938-A1 | GIP DERIVATIVES AND USES THEREOF | NOVO NORDISK AS (DK) | 2024-06-13 | — | — | US | disclosed |
| US-11633459-B2 | GIP derivatives and uses thereof | NOVO NORDISK A/S (DK) | 2023-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11633459-B2 | GIP derivatives and uses thereof | GIPR, GLP1R, GPR119 | ERAP2 342/4885ERAP1 216/4885LNPEP 217/4885 |
| US-20240190938-A1 | GIP DERIVATIVES AND USES THEREOF | GIPR, GLP1R, GPR119 | ERAP2 342/4885ERAP1 216/4885LNPEP 217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.